

1FW 1656

I hereby certify that this correspondence is being deposited
as first-class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail-Stop: Amendment

Attorney Docket No: 0267us310

On: 14 Nov. 2006

By: Ann Massey
Ann Massey

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Jesper M. Haaning, *et al.*

Examiner: Holly G. Schnizer

Application No.: 10/529,624

Art Unit: 1656

Filed: October 13, 2005

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR § 1.97 AND § 1.98

For: FVII or FVIIa Variants Having Increased
Clotting Activity

Mail-Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached form PTO/SB/08A-B are being called to the attention of the Examiner. Copies of the cited references – except copies of the cited U.S. patents and published U.S. patent applications – are enclosed. As provided in 37 CFR § 1.98, copies of cited U.S. patents and published U.S. patent applications need not be provided.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the “references cited” on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Jesper M. Haaning, *et al.*
Application No.: 10/529,624
Supplemental Information Disclosure Statement
Page 2 of 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicants believe that no fee is due, as this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. However, in the event the Office determines that any fees are due, please deduct such fees from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from or credit any overpayment to the above-noted Deposit Account.

Respectfully submitted,



Margaret A. Powers
Reg. No. 39,804

November 14, 2006
Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5809
Facsimile: (650) 298-5446
Customer No. 30560



Please type a plus sign (+) inside this box → +

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a

valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission 8

Application Number

10/529,624

Filing Date

October 13, 2005

First Named Inventor

Jesper M/ Haaning

Group Art Unit

1656

Examiner Name

Holly G. Schnizer

Attorney Docket Number

0267us310

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Response
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):
 - Form PTO/SB/08A-B (5 pp.)
 - Copies of 80 cited references (refs. 21, 26-104)
 - Return Postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Margaret A. Powers, Maxygen, Inc., Reg. No. 39,804

Signature

Date

November 14, 2006


Certificate of Mailing under 37 C.F.R. §1.8

I hereby certify that this is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, Mail Stop: Amendment on this date:

Typed or Printed Name: Ann Massey

Date: November 14, 2006


Signature: Ann Massey



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/529,624
	Filing Date	October 13, 2005
	First Named Inventor	Jesper M. Haaning
	Group Art Unit	1656
	Examiner Name	Holly G. Schnizer
	Attorney Docket Number	0267us310

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,093,317		Lewis et al.	03-03-1992	
	2	5,258,288		Wydro et al.	11-02-1993	
	3	5,504,064		Morrissey et al.	04-02-1996	
	4	5,516,640		Watanabe et al.	05-14-1996	
	5	5,788,965		Berkner et al.	08-04-1998	
	6	5,817,788		Berkner et al.	10-06-1998	
	7	5,824,639		Berkner	10-20-1998	
	8	5,833,982		Berkner et al.	11-20-1998	
	9	5,837,843		Smirnov et al.	11-17-1998	
	10	5,847,085		Esmon et al.	12-08-1998	
	11	6,100,061		Reiter et al.	08-08-2000	
	12	6,423,826		Nelsestuen et al.	07-23-2002	
	13	6,475,725		Reiter et al.	11-05-2002	
	14	6,693,075		Nelsestuen	02-17-2004	
	15	6,747,003		Nelsestuen	06-08-2004	
	16	6,762,286		Nelsestuen	07-13-2004	
	17	6,806,063		Pedersen et al.	10-19-2004	
	18	6,903,069		Pingel et al.	09-26-2002	
	19	7,026,524		Persson et al.	04-11-2006	
	20	US2003/0100506		Nelsestuen	05-29-2003	
	21	Pending claims of US2003/0100506		Nelsestuen	05-29-2003	
	22	US2003/0100740		Persson et al.	05-29-2003	
	23	US2003/0104978		Persson et al.	06-05-2003	
	24	US2003/0211094		Nelsestuen	11-13-2003	
	25	US2003/0211460		Nelsestuen	11-13-2003	
	26	Pending claims of USSN 10/031,005,		Nelsestuen	Parent application published as	
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/529,624
	Filing Date	October 13, 2005
	First Named Inventor	Jesper M. Haaning
	Group Art Unit	1656
	Examiner Name	Holly G. Schnizer
	Attorney Docket Number	0267us310


		which is a national phase appn of WO 00/66753, which was cited on previously filed IDS/1449)			WO 00/66753	
--	--	--	--	--	-------------	--

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	27	WO	02/03075		University of Minnesota	01-10-2002		
	28	WO	02/02764		University of Minnesota	01-10-2002		
	29	WO	02/29025		Novo Nordisk A/S	04-11-2002		
	30	EP	0 296 413	A2	Hoechst Japan	12-28-1988		
	31	EP	0 354 504	A2	Hoechst Japan	02-12-1990		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
	32	Arnlijots et al., "Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa," J. Vasc. Surg., 1997, 25(2):341-346		
	33	Bauer, "Treatment of factor VII deficiency with recombinant factor VIIa," Haemostasis, 1996, 26 (Suppl. 1):155-158		
	34	Broze et al., "Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII," J. Clin. Invest., 1985, 76:937-946		
	35	Choudhri et al., "Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage," J. Exp. Med., 1999, 190:91-99		
	36	Christiansen et al., "Hydrophobic Amino Acid Residues of Human Anticoagulation Protein C that Contribute to its Functional Binding to Phospholipid Vesicles," Biochemistry, 1995, 34:10376-10382		
	37	Dackiw et al., "Prevention of endotoxin-induced mortality by antitissue factor immunization," Arch. Surg., 1996, 131:1273-1278		
	38	Dahlback, "Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboemolism," Blood, 1995, 85:607-614		
	39	Database EMBL, "Coagulation factor VII (EC 3.4.21.21)(Serum prothrombin conversion accelerator)," "Bovine Factor VII. Its purification and complete amino acid sequence," ID FA7_BOVIN, August 1, 1991 (3 pages)		
	40	"Docking of Tissue Factor and Factor VIIa Initiates Blood Coagulation," at http://www.sdsc.edu.IOTW/week46.96/ (1996)		
	41	Esmon et al., "Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C," J. Biol. Chem., 1982, 257:859-864		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/529,624
	Filing Date	October 13, 2005
	First Named Inventor	Jesper M. Haaning
	Group Art Unit	1656
	Examiner Name	Holly G. Schnizer
	Attorney Docket Number	0267us310

42	Evans, Jr. and Nelsestuen, "Importance of cis-Proline 22 in the Membrane-Binding Conformation of Bovine Prothrombin," Biochemistry, 1996, 35:8210-8215
43	Evans and Nelsestuen, "Importance of Cis-Proline 22 and the Aromatic Stack (Residues 41-45) for Prothrombin-Membrane Binding," Protein Sci., 1996, 5(Suppl. 1):163, Abstract #606-S
44	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA, 1987, 84:7413-7417
45	Fiore et al., "The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa," J. Biol. Chem., 1994, 269:143-149
46	Freedman et al., "Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX," J. Biol. Chem., 1996, 271(27):16227-16236
47	Furie and Furie, "The molecular basis of blood coagulation," Cell, 1988, 53:505-518
48	Guo et al., "Protein Tolerance to random amino acid change," Proc. Natl. Acad. Sci. 101(25):9205-9210 (2004)
49	Han et al., "Isolation of a protein Z-dependent plasma protease inhibitor," Proc. Natl. Acad. Sci. USA, 1998, 95:9250-9255
50	He et al., "Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein-S-defining modules important for the species specificity of the activated protein C cofactor activity," Eur. J. Biochem., 1995, 227:433-440
51	Hedner et al., "Recombinant Activated Factor VII in the Treatment of Bleeding Episodes in Patients with Inherited and Acquired Bleeding Disorders," Transfus. Med. Rev., 1993, 7:78-83
52	Hope et al., "Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure. Characterization of Size Distribution, Trapped Volume and Ability to Maintain a Membrane Potential," Biochem. Biophys. Acta, 1985, 812:55-65
53	Hoskins et al., "Cloning and characterization of human liver cDNA encoding a protein S precursor," Proc. Natl. Acad. Sci. USA, 1987, 84:349-353
54	Huang, , "Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics," Biochemistry, Biochemistry, 1969, 8:344-352
55	Humphries et al., "Chemical methods of protein synthesis and modification," Curr. Opin. Biotechnol., 1991, 2(4):539-543
56	Jurlander et al., "Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development," Semin. Thromb. Hemos., 2001, 27(4):373-383
57	Leff, "Genetically Stripped-Down Factor VIII Corrects Bleeding Disorder in Hemophilic Mice," BioWorld Today, 1997, 8(209):1,6
58	Lu and Nelsestuen, "Dynamic Features of Prothrombin Interaction with Phospholipid Vesicles of Different Size and Composition: Implications for Protein - Membrane Contact," Biochemistry, 1996, 35:8193-8200
59	Lu and Nelsestuen, "The prothrombinase reaction: "mechanism switching" between Michaelis-Menten and non-Michaelis-Menten behaviors," Biochemistry, 1996, 35:8201-8209
60	Martinez et al., "Underdecarboxylation of Vitamin K-Dependent Proteins: Occasionally Severe, Possibly Universal," Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics, May 27-31, 2001, Chicago, Illinois, 2 pgs.
61	Matsubara et al., "A receptor tyrosine kinase, Sky, and its ligand Gas 6 are expressed in gonads and support primordial germ cell growth or survival in culture," Dev. Biol., 1996, 180:499-510
62	Mayer et al., "Prothrombin Association with Phospholipid Monolayers," Biochemistry, 1983, 22(2):316-321
63	Mayer, "Ultra-early hemostatic therapy for intracerebral hemorrhage," Stroke 2003, 34:224-229
64	McDonald et al., "Comparison of Naturally Occurring Vitamin K-dependent Proteins: Correlation of

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/529,624
	Filing Date	October 13, 2005
	First Named Inventor	Jesper M. Haaning
	Group Art Unit	1656
	Examiner Name	Holly G. Schnizer
	Attorney Docket Number	0267us310

		Amino Acid Sequences and Membrane Binding Properties Suggests a Membrane Contact Site," Biochemistry, 1997, 36:5120-5127	
	65	McDonald et al., "Ionic Properties of Membrane Association by Vitamin K-Dependent Proteins: The Case for Univalency," Biochemistry, 1997, 36(50):15589-15598	
	66	Morrissey et al., "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation," Blood, 1993, 81(3):734-744	
	67	Muir et al., "The chemical synthesis of proteins," Curr. Opin. Biotechnol., 1993, 4(4):420-427	
	68	Nakagaki et al., "Initiation of the Extrinsic Pathway of Blood Coagulation: Evidence for the Tissue Factor Dependent Autoactivation of Human Coagulation Factor VII," Biochemistry, 1991, 30:10819-10824	
	69	Nelsestuen et al., "Membrane association with multiple calcium ions: vitamin-K-dependent proteins, annexins and pentraxins," Current Opinion in Structural Biology 9:433-437 (1999)	
	70	Nelsestuen, "Enhancement of Vitamin-K-Dependent Protein Function by Modification of the gamma-Carboxyglutamic Acid Domain: Studies of Protein C and Factor VII," Trends Cardiovasc. Med. 9(6):162-167 (1999)	
	71	Nelsestuen et al., "Vitamin K-Dependent Proteins," in 58 VITAMINS AND HORMONES: ADVANCES IN RESEARCH AND APPLICATIONS (Gerald Litwack ed., Academic Press, 2000), pp. 355-389	
	72	Nelsestuen et al., "Equilibria Involved in Prothrombin- and Blood Clotting Factor X-Membrane Binding," Biochemistry, 1977, 16(19):4164-4171	
	73	Nelsestuen and Suttie, "Properties of Asialo and Aglycoprothrombin," Biochem. Biophys. Res. Commun., 1971, 45:198-203	
	74	Nicolaes et al., "A prothrombinase-based assay for detection of resistance to activated protein C," Thromb. Haemost., 1996, 76:404-410	
	75	Nicolaisen et al., "Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use," Thromb. Haemost., 1996, 76:200-204	
	76	Okafuji et al., EMBL Data Library, Accession No. S18994, Sept. 10, 1999 (protein C activated precursor, sequence) (Score Search)	
	77	Perera et al., "Trans-cis Isomerization of Proline 22 in Bovine Prothrombin Fragment 1: A Surprising Result of Structural Characterization," Biochemistry, 1998, 37:10920-10927	
	78	Petersen et al., "Quenching of the amidolytic activity of one-chain tissue-type plasminogen activator by mutation of lysine-416," Biochemistry, 1990, 29:3451-3457	
	79	Petrovan et al., "Residue Met ¹⁵⁶ contributes to the labile enzyme conformation of coagulation factor VIIa," J. Biol. Chem. 2001, 276(9):6616-6620	
	80	Ratcliffe et al., "The Importance of Specific γ-Carboxyglutamic Acid Residues in Prothrombin," J. Biol. Chem., 1993, 268(32):24339-24345	
	81	Resnick and Nelsestuen, "Prothrombin-Membrane Interaction. Effects of Ionic Strength, pH, and Temperature," Biochemistry, 1980, 19(13):3028-3033	
	82	Rezaie and Esmon, "The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives," J. Biol. Chem., 1992, 267:26104-26109	
	83	Sakai et al., "The γ-Carboxyglutamic Acid Domain of Human Factor VIIA is Essential for Its Interaction with Cell Surface Tissue Factor," J. Biol. Chem., 1990, 265(4):1890-1894	
	84	Schmidet et al., "Organization of the Human Protein S Genes," J. Biol. Chem., 1990, 265(34):7845-7852	
	85	Schulman et al., "Feasibility of using recombinant factor VIIa in continuous infusion," Thromb. Haemost., 1996, 75(3):432-436	
	86	Schwalbe et al., "Protein Structural Requirements and Properties of Membrane Binding by γ-Carboxyglutamic Acid-containing Plasma Proteins and Peptides," J. Biol. Chem., 1989, 264:20288-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/529,624
	Filing Date	October 13, 2005
	First Named Inventor	Jesper M. Haaning
	Group Art Unit	1656
	Examiner Name	Holly G. Schnizer
	Attorney Docket Number	0267us310

		20296	
87		Seffernick et al., "Melamine Deaminase and Atrazine Chlorohydrolase: 98 Percent Identical but Functionally Different," J. Bacteriol. 183(8):2405-2410 (2001)	
88		Seshadri et al., "Differences in the Metal Ion Structure between Sr- and Ca-Prothrombin Fragment 1," Biochemistry, 1994, 33:1087-1092	
89		Shen et al., "Enhancing the Activity of Protein C by Mutagenesis to Improve the Membrane-Binding Site: Studies Related to Proline 10," Biochemistry, 1997, 36(51):16025-16031	
90		Shen et al., "Enhancement of Human Protein C Function by Site-directed Mutagenesis of the γ -Carboxyglutamic Acid Domain," J. Biol. Chem., 1998, 273(47):31086-31091	
91		Smirnov et al., "A Chimeric Protein C Containing the Prothrombin Gla Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity," J. Biol. Chem., 1998, 273(15):9031-9040	
92		Thariath et al., "Highly conserved residue arginine-15 is required for the Ca^{2+} -dependent properties of the γ -carboxyglutamic acid domain of human anticoagulation Protein C and activated Protein C," Biochem. J., 1997, 322:309-315	
93		Thim et al., "Amino Acid Sequence and Posttranslational Modification of Human Factor VIIa from Plasma and Transfected Baby Hamster Kidney Cells," Biochemistry, 1988, 27:7785-7793	
94		Thomsen et al., "Pharmacokinetics of recombinant factor VIIa in the rat - a comparison of bio-, immuno- and isotope assays," Thromb. Haemost., 1993, 70(3):458-464	
95		Vallette et al., "Construction of mutant and chimeric genes using the polymerase chain reaction," Nucleic Acids Res., 1989, 17(2):723-733	
96		Vrana et al., "Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family," Cancer Res., 56:5063-5070 (1996)	
97		Weber et al., "Modifications of Bovine Prothrombin Fragment 1 in the Presence and Absence of Ca(II) Ions," J. Biol. Chem., 1992, 267(7):4564-4569	
98		Wei et al., "Kinetic and Mechanistic Analysis of Prothrombin-Membrane Binding by Stopped-Flow Light Scattering," Biochemistry, 1982, 21:1949-1959	
99		Wells, "Additivity of Mutational Effects in Proteins," Biochem. 29(17):8509-8517 (1990)	
100		Welsch et al., "Chemical Modification of Prothrombin Fragment 1: Documentation of Sequential, Two-Stage Loss of Protein Function," Biochemistry, 1988, 27:4933-4938	
101		Welsch and Nelsestuen, "Amino-terminal alanine functions in a calcium-specific process essential for membrane binding by prothrombin fragment 1," Biochemistry, 1988, 27:4939-4945	
102		Yan et al., "Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell Lines," Bio/Technology, 1990, 8:655-661	
103		Zhang et al., "Role of Individual γ -Carboxyglutamic Acid Residues of Activated Human Protein C in Defining its In Vitro Anticoagulant Activity," Blood, 1992, 80(4):942-952	
104		Zwaal et al., "Lipid-protein interactions in blood coagulation," Biochimica et Biophysica Acta, 1998, 1376:433-453	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.